BIOVENTUS INC. - CLASS A COMMON STOCK

Bioventus to Present at the Canaccord Genuity Musculoskeletal Conference

16 мар 2022 06:00:00 Источник Nasdaq GlobeNewswire

Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance

10 мар 2022 06:00:03 Источник Nasdaq GlobeNewswire

Bioventus Receives 510(k) Clearance for StimRouter Pain Management Device

01 мар 2022 06:00:01 Источник Nasdaq GlobeNewswire

Bioventus Appoints Mark Singleton as Chief Financial Officer

28 фев 2022 06:00:00 Источник Nasdaq GlobeNewswire

Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022

22 фев 2022 06:00:01 Источник Nasdaq GlobeNewswire

Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue

11 янв 2022 06:00:00 Источник Nasdaq GlobeNewswire

Bioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference

28 дек 2021 06:00:00 Источник Nasdaq GlobeNewswire

Bioventus Appoints Michelle McMurry-Heath to Board of Directors

21 дек 2021 08:25:00 Источник Nasdaq GlobeNewswire

Bioventus Receives US FDA Clearance for BoneScalpel® Access™

20 дек 2021 07:30:00 Источник Nasdaq GlobeNewswire

Bioventus to Expand Operations and Manufacturing in Memphis

18 ноя 2021 07:45:00 Источник Nasdaq GlobeNewswire

Bioventus Announces Chief Financial Officer Transition Plan

15 ноя 2021 06:30:01 Источник Nasdaq GlobeNewswire

Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance

09 ноя 2021 06:00:02 Источник Nasdaq GlobeNewswire

Sharon Klugewicz Joins Bioventus as Senior Vice President, Quality and Regulatory Affairs

01 ноя 2021 07:30:00 Источник Nasdaq GlobeNewswire

Bioventus Completes the Acquisition of Misonix

29 окт 2021 07:25:18 Источник Nasdaq GlobeNewswire

Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021

27 окт 2021 15:15:00 Источник Nasdaq GlobeNewswire

Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus

26 окт 2021 15:15:00 Источник Nasdaq GlobeNewswire

BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration

18 окт 2021 07:00:01 Источник Nasdaq GlobeNewswire

DUROLANE® Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic Surgeons

20 сен 2021 07:30:00 Источник Nasdaq GlobeNewswire

Bioventus Proceeds with Option Structure Agreement with CartiHeal

30 авг 2021 06:30:00 Источник Nasdaq GlobeNewswire

Bioventus Invests in Trice Medical Minimally Invasive Technologies

25 авг 2021 15:05:00 Источник Nasdaq GlobeNewswire